Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)
Author(s)
Taweesak Wannachalee, .1, Pimjai Anthanont, .2, Ratiporn Chinthammit, .3, Woralak Chumchujan, .3, Supawan Buranapin, .4.
1Division of Endocrinology and Metabolism, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, Bangkok, Thailand, 2Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand, Pathum Thani, Thailand, 3Novo Nordisk Pharma Thailand Ltd., Bangkok, Thailand, Bangkok, Thailand, 4Section of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand.
1Division of Endocrinology and Metabolism, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, Bangkok, Thailand, 2Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand, Pathum Thani, Thailand, 3Novo Nordisk Pharma Thailand Ltd., Bangkok, Thailand, Bangkok, Thailand, 4Section of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand.
Presentation Documents
OBJECTIVES: Although the efficacy and safety of oral semaglutide have been established in the phase 3 PIONEER clinical program, real-world clinical outcome data in the Thai population is limited. This study evaluates the real-world impact of oral semaglutide on glycemic control and weight management in Thai adults with Type 2 Diabetes (T2D). The primary objective is to assess the mean change in HbA1c levels among Thai adults with T2D initiating oral semaglutide treatment without prior injectable glucose-lowering medications. Secondary objectives include characterizing patient demographics and evaluating changes in body weight.
METHODS: This multi-centre, retrospective study collected data from electronic health records and paper chart reviews of adults diagnosed with T2D across four medical schools in Thailand. Patients started oral semaglutide (3 mg, 7 mg, or 14 mg based on physician discretion) between April 2022 and October 2023. Eligible patients were treated with oral semaglutide for at least 6 months without interruption. Descriptive statistics summarized demographics, and mean changes in HbA1c and body weight were calculated from baseline to end of 26 ± 6 weeks treatment period.
RESULTS: A total of 195 eligible patients were analyzed. Participants had a mean age of 56.5 years (SD: 11.9), mean BMI of 30.9 kg/m² (SD: 5.9), and 58.5% were female. The mean baseline HbA1c was 7.4% (SD: 1.2), with an overall mean change of -0.8% (p<0.0001). The mean duration of T2D was 8.8 years (SD: 7.3). Mean weight loss was -5.0 kg (p<0.0001), or -6.0% (p<0.0001) from baseline.
CONCLUSIONS: This study highlights the real-world clinical outcomes of oral semaglutide in achieving clinically relevant reductions in HbA1c and body weight in Thai adults with T2D, showcasing a diverse patient demographic that enhances the relevance of these findings.
METHODS: This multi-centre, retrospective study collected data from electronic health records and paper chart reviews of adults diagnosed with T2D across four medical schools in Thailand. Patients started oral semaglutide (3 mg, 7 mg, or 14 mg based on physician discretion) between April 2022 and October 2023. Eligible patients were treated with oral semaglutide for at least 6 months without interruption. Descriptive statistics summarized demographics, and mean changes in HbA1c and body weight were calculated from baseline to end of 26 ± 6 weeks treatment period.
RESULTS: A total of 195 eligible patients were analyzed. Participants had a mean age of 56.5 years (SD: 11.9), mean BMI of 30.9 kg/m² (SD: 5.9), and 58.5% were female. The mean baseline HbA1c was 7.4% (SD: 1.2), with an overall mean change of -0.8% (p<0.0001). The mean duration of T2D was 8.8 years (SD: 7.3). Mean weight loss was -5.0 kg (p<0.0001), or -6.0% (p<0.0001) from baseline.
CONCLUSIONS: This study highlights the real-world clinical outcomes of oral semaglutide in achieving clinically relevant reductions in HbA1c and body weight in Thai adults with T2D, showcasing a diverse patient demographic that enhances the relevance of these findings.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO202
Topic
Clinical Outcomes, Epidemiology & Public Health, Study Approaches
Topic Subcategory
Clinical Outcomes Assessment, Relating Intermediate to Long-term Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas, Urinary/Kidney Disorders